SCHEMBL3540571

SCHEMBL3540571

CCN1CCN(c2ccc3nc(-c4n[nH]c5ccc(Oc6ccc(F)cc6)cc45)n(C)c3c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.46
SCN9A Q15858 1/20 0.43
ABL1 P00519 5/20 0.43
LRRK2 Q5S007 5/20 0.43
FLT1 P17948 1/20 0.42
NTRK1 P04629 1/20 0.40
FGFR2 P21802 2/20 0.40
KDR P35968 2/20 0.39
PDGFRA P16234 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
TRPV4 Q9HBA0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537434 0.93 FGFR1 (0.44) FGFR1SCN9AABL1LRRK2FLT1
SCHEMBL3535310 0.92 FGFR1 (0.49) FGFR1SCN9AABL1LRRK2FLT1
SCHEMBL3612553 0.92 ABL1 (0.51) FGFR1ABL1LRRK2FLT1FGFR2
SCHEMBL3544861 0.90 FGFR1 (0.44) FGFR1SCN9AABL1LRRK2FLT1
SCHEMBL3536581 0.88 ABL1 (0.52) FGFR1ABL1LRRK2FLT1FGFR2
SCHEMBL3540626 0.88 FGFR1 (0.44) FGFR1ABL1LRRK2FLT1FGFR2
SCHEMBL3544838 0.88 ABL1 (0.53) FGFR1ABL1LRRK2FLT1FGFR2
SCHEMBL3535696 0.87 FGFR1 (0.44) FGFR1ABL1LRRK2FLT1FGFR2
SCHEMBL3538866 0.85 FGFR1 (0.51) FGFR1FLT1FGFR2KDRFGFR3
SCHEMBL3539022 0.84 FGFR1 (0.43) FGFR1ABL1LRRK2FLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885SCN9A 2584/4885ABL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.